BTCRC-LYM17-145: Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination with the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients with Relapsed/Refractory Indolent Lymphoma. Big Ten Cancer Research Consortium

BTCRC-LYM17-145: Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination with the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients with Relapsed/Refractory Indolent Lymphoma. Big Ten Cancer Research Consortium

The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Clink on the link to learn about the details regarding the study on clinicaltrials.gov.

For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.

BTCRC-LYM17-145: Phase IB Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination with the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients with Relapsed/Refractory Indolent Lymphoma. Big Ten Cancer Research Consortium

Sponsor: Big Ten Cancer Research Consortium

Principal Investigator: John Quigley, MD

Leave a Reply